“Over-expression of the PCA3 gene is highly specific to cancerous prostate tissue,” John Wei, MD, MS, Professor of Urology at the University of Michigan Health System in Ann Arbor, said in a company-issued statement. “When evaluated with other risk factors, the PROGENSA PCA3 assay fills an important unmet clinical need by helping physicians identify which men suspected of having prostate cancer should undergo a repeat prostate biopsy.”
I’ve been using the PCA-3 test for a few years. I have used it for this indication, as well as for patients who opt for active surveillance for their prostate cancer. I am glad the test was approved for this use by the FDA.